Q1 EPS Forecast for Monogram Orthopaedics Raised by Analyst

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Equities research analysts at Roth Capital raised their Q1 2025 earnings per share estimates for Monogram Orthopaedics in a note issued to investors on Thursday, March 13th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.11). The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($0.63) EPS and FY2027 earnings at ($0.24) EPS.

Separately, Roth Mkm lifted their price target on Monogram Orthopaedics from $4.00 to $5.40 and gave the stock a “buy” rating in a research note on Tuesday.

Monogram Orthopaedics Stock Down 6.5 %

Shares of MGRM stock opened at $3.43 on Monday. The business has a 50-day moving average price of $2.58 and a two-hundred day moving average price of $2.50. Monogram Orthopaedics has a 12-month low of $1.53 and a 12-month high of $4.90. The firm has a market cap of $121.04 million, a P/E ratio of -7.30 and a beta of 1.66.

Monogram Orthopaedics (NASDAQ:MGRM) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. State Street Corp purchased a new position in Monogram Orthopaedics during the 3rd quarter valued at about $62,000. Barclays PLC purchased a new position in Monogram Orthopaedics during the 3rd quarter valued at about $29,000. Geode Capital Management LLC boosted its position in Monogram Orthopaedics by 1,267.4% during the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock valued at $557,000 after acquiring an additional 194,776 shares in the last quarter. Fiduciary Family Office LLC bought a new stake in Monogram Orthopaedics during the 4th quarter valued at approximately $70,000. Finally, Commonwealth Equity Services LLC boosted its position in Monogram Orthopaedics by 21.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 41,628 shares of the company’s stock valued at $99,000 after acquiring an additional 7,366 shares in the last quarter. Hedge funds and other institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.